BGM Group (BGM) Competitors

$0.28 +0.01 (+2.73%)

Closing price 04:00 PM Eastern

Extended Trading

$0.30 +0.02 (+5.49%)

As of 07:06 PM Eastern

BGM vs. CUE, ANIX, ENGN, UPXI, and COYA

Should you buy BGM Group stock or one of its competitors? MarketBeat compares BGM Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BGM Group include Cue Biopharma (CUE), Anixa Biosciences (ANIX), enGene (ENGN), Upexi (UPXI), and Coya Therapeutics (COYA). These companies are all part of the "pharmaceutical products" industry.

How does BGM Group compare to Cue Biopharma?

BGM Group (NASDAQ:BGM) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.

BGM Group has a beta of 1.79, meaning that its share price is 79% more volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.37, meaning that its share price is 137% more volatile than the broader market.

In the previous week, Cue Biopharma had 3 more articles in the media than BGM Group. MarketBeat recorded 4 mentions for Cue Biopharma and 1 mentions for BGM Group. Cue Biopharma's average media sentiment score of 0.66 beat BGM Group's score of 0.00 indicating that Cue Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

35.0% of Cue Biopharma shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 1.8% of Cue Biopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BGM Group has higher earnings, but lower revenue than Cue Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.09	-$1.44M	N/A	N/A
Cue Biopharma	$27.47M	2.99	-$26.60M	-$5.58	N/A

BGM Group has a net margin of 0.00% compared to Cue Biopharma's net margin of -59.65%. BGM Group's return on equity of 0.00% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Cue Biopharma	-59.65%	-98.30%	-53.69%

Summary

Cue Biopharma beats BGM Group on 6 of the 11 factors compared between the two stocks.

How does BGM Group compare to Anixa Biosciences?

BGM Group (NASDAQ:BGM) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability and analyst recommendations.

BGM Group has higher revenue and earnings than Anixa Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.09	-$1.44M	N/A	N/A
Anixa Biosciences	$210K	426.31	-$10.93M	-$0.33	N/A

BGM Group has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Anixa Biosciences has a consensus target price of $8.50, suggesting a potential upside of 218.35%. Given Anixa Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

BGM Group's return on equity of 0.00% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
Anixa Biosciences	N/A	-70.95%	-62.53%

29.1% of Anixa Biosciences shares are owned by institutional investors. 58.7% of BGM Group shares are owned by insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, BGM Group and BGM Group both had 1 articles in the media. BGM Group's average media sentiment score of 0.00 equaled Anixa Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BGM Group beats Anixa Biosciences on 6 of the 11 factors compared between the two stocks.

How does BGM Group compare to enGene?

BGM Group (NASDAQ:BGM) and enGene (NASDAQ:ENGN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

64.2% of enGene shares are owned by institutional investors. 58.7% of BGM Group shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BGM Group's return on equity of 0.00% beat enGene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BGM Group	N/A	N/A	N/A
enGene	N/A	-55.83%	-45.74%

BGM Group has higher revenue and earnings than enGene.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BGM Group	$25.10M	1.09	-$1.44M	N/A	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

In the previous week, enGene had 9 more articles in the media than BGM Group. MarketBeat recorded 10 mentions for enGene and 1 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 beat enGene's score of -0.04 indicating that BGM Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
enGene	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

enGene has a consensus price target of $12.68, indicating a potential upside of 728.88%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

BGM Group has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market. Comparatively, enGene has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market.

Summary

BGM Group beats enGene on 7 of the 12 factors compared between the two stocks.

How does BGM Group compare to Upexi?

Upexi (NASDAQ:UPXI) and BGM Group (NASDAQ:BGM) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Upexi has a beta of -0.32, indicating that its stock price is 132% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market.

Upexi presently has a consensus target price of $8.33, suggesting a potential upside of 545.99%. Given Upexi's stronger consensus rating and higher possible upside, equities research analysts plainly believe Upexi is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upexi	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

5.7% of Upexi shares are owned by institutional investors. 9.0% of Upexi shares are owned by insiders. Comparatively, 58.7% of BGM Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BGM Group has a net margin of 0.00% compared to Upexi's net margin of -874.00%. BGM Group's return on equity of 0.00% beat Upexi's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upexi	-874.00%	-66.70%	-19.56%
BGM Group	N/A	N/A	N/A

In the previous week, Upexi had 6 more articles in the media than BGM Group. MarketBeat recorded 7 mentions for Upexi and 1 mentions for BGM Group. BGM Group's average media sentiment score of 0.00 beat Upexi's score of -0.51 indicating that BGM Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upexi	0 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Negative
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BGM Group has lower revenue, but higher earnings than Upexi.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upexi	$26.14M	3.47	-$13.68M	-$3.23	N/A
BGM Group	$25.10M	1.09	-$1.44M	N/A	N/A

Summary

Upexi beats BGM Group on 8 of the 15 factors compared between the two stocks.

How does BGM Group compare to Coya Therapeutics?

Coya Therapeutics (NASDAQ:COYA) and BGM Group (NASDAQ:BGM) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Coya Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market. Comparatively, BGM Group has a beta of 1.79, suggesting that its stock price is 79% more volatile than the broader market.

39.8% of Coya Therapeutics shares are owned by institutional investors. 12.0% of Coya Therapeutics shares are owned by company insiders. Comparatively, 58.7% of BGM Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Coya Therapeutics had 6 more articles in the media than BGM Group. MarketBeat recorded 7 mentions for Coya Therapeutics and 1 mentions for BGM Group. Coya Therapeutics' average media sentiment score of 0.45 beat BGM Group's score of 0.00 indicating that Coya Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coya Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BGM Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Coya Therapeutics currently has a consensus price target of $16.00, suggesting a potential upside of 250.11%. Given Coya Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Coya Therapeutics is more favorable than BGM Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
BGM Group	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

BGM Group has a net margin of 0.00% compared to Coya Therapeutics' net margin of -266.10%. BGM Group's return on equity of 0.00% beat Coya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coya Therapeutics	-266.10%	-55.86%	-48.86%
BGM Group	N/A	N/A	N/A

BGM Group has higher revenue and earnings than Coya Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coya Therapeutics	$7.94M	13.50	-$21.23M	-$1.15	N/A
BGM Group	$25.10M	1.09	-$1.44M	N/A	N/A

Summary

Coya Therapeutics and BGM Group tied by winning 7 of the 14 factors compared between the two stocks.

Get BGM Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BGM vs. The Competition

Export

Metric	BGM Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27.47M	$3.25B	$6.25B	$12.10B
Dividend Yield	N/A	2.33%	2.80%	5.32%
P/E Ratio	N/A	18.70	20.58	25.11
Price / Sales	1.09	278.20	577.42	91.32
Price / Cash	N/A	55.27	27.48	37.30
Price / Book	0.04	6.57	9.68	6.60
Net Income	-$1.44M	$24.30M	$3.55B	$335.71M
7 Day Performance	8.15%	-3.56%	-2.07%	-2.03%
1 Month Performance	-12.54%	-7.86%	-3.90%	-1.90%
1 Year Performance	-97.68%	51.80%	29.39%	27.36%

BGM Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BGM BGM Group	0.2569 of 5 stars	$0.28 +2.7%	N/A	-97.8%	$27.47M	$25.10M	N/A	298	News Coverage Gap Up
CUE Cue Biopharma	0.9798 of 5 stars	$29.26 -6.6%	N/A	-96.7%	$101.96M	$27.47M	N/A	60	Earnings Report Analyst Upgrade
ANIX Anixa Biosciences	1.8698 of 5 stars	$2.95 -2.6%	$8.50 +188.1%	+4.2%	$101.59M	$210K	N/A	5
ENGN enGene	3.4249 of 5 stars	$1.44 -3.4%	$13.41 +831.2%	-54.5%	$99.81M	N/A	N/A	31	News Coverage
UPXI Upexi	1.5393 of 5 stars	$1.35 -8.2%	$8.33 +517.3%	-87.0%	$98.37M	$24.74M	N/A	130	Earnings Report Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BGM) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BGM Group (BGM) Competitors

BGM vs. CUE, ANIX, ENGN, UPXI, and COYA

How does BGM Group compare to Cue Biopharma?

Summary

How does BGM Group compare to Anixa Biosciences?

Summary

How does BGM Group compare to enGene?

Summary

How does BGM Group compare to Upexi?

Summary

How does BGM Group compare to Coya Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BGM Group (BGM) Competitors

BGM vs. CUE, ANIX, ENGN, UPXI, and COYA

How does BGM Group compare to Cue Biopharma?

Which has more volatility & risk, BGM or CUE?

Does the media refer more to BGM or CUE?

Do analysts prefer BGM or CUE?

Do insiders and institutionals believe in BGM or CUE?

Which has preferable earnings and valuation, BGM or CUE?

Is BGM or CUE more profitable?

Summary

How does BGM Group compare to Anixa Biosciences?

Which has higher earnings and valuation, BGM or ANIX?

Which has more risk and volatility, BGM or ANIX?

Do analysts recommend BGM or ANIX?

Is BGM or ANIX more profitable?

Do insiders and institutionals have more ownership in BGM or ANIX?

Does the media prefer BGM or ANIX?

Summary

How does BGM Group compare to enGene?

Do insiders & institutionals believe in BGM or ENGN?

Is BGM or ENGN more profitable?

Which has stronger earnings & valuation, BGM or ENGN?

Does the media favor BGM or ENGN?

Do analysts rate BGM or ENGN?

Which has more risk and volatility, BGM or ENGN?

Summary

How does BGM Group compare to Upexi?

Which has more volatility and risk, UPXI or BGM?

Do analysts prefer UPXI or BGM?

Do insiders & institutionals hold more shares of UPXI or BGM?

Is UPXI or BGM more profitable?

Does the media prefer UPXI or BGM?

Which has stronger valuation and earnings, UPXI or BGM?

Summary

How does BGM Group compare to Coya Therapeutics?

Which has more volatility and risk, COYA or BGM?

Do institutionals and insiders have more ownership in COYA or BGM?

Does the media refer more to COYA or BGM?

Do analysts recommend COYA or BGM?

Is COYA or BGM more profitable?

Which has stronger earnings and valuation, COYA or BGM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BGM vs. The Competition

BGM Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools